KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: A systematic review and meta‐analysis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The authors conducted a systematic review and meta‐analysis to examine whether patients who had metastatic colorectal cancer (mCRC) with the v‐Ki‐ ras 2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) p.G13D mutation (an amino acid substitution at position 13 in KRAS from a glycine to an aspartic acid) and received cetuximab treatment had better clinical outcomes than patients who had mCRC tumors with KRAS codon 12 mutations. METHODS: Relevant studies were identified by a search of MEDLINE, EMBASE, the Chinese Biomedical Database, and Wan Fang Digital Journals from inception to October 2011. The primary clinical outcomes included the objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS). The pooled relative risk (RR) or hazard ratio (HR) was estimated by using fixed‐effects or random‐effects models according to heterogeneity between studies. RESULTS: Ten studies were considered eligible that included 1487 patients with mCRC. Patients who had tumors with the KRAS p.G13D mutation had a significantly higher ORR (10 studies; RR, 1.642; 95% confidence interval [CI], 1.131‐2.384), longer PFS (1 study; HR, 0.54; 95% CI, 0.36‐0.81), and longer OS (1 study; HR, 0.52; 95% CI, 0.33‐0.80) than patients who had tumors with KRAS codon 12 mutations. Compared with patients who had KRAS wild‐type tumors, patients with the p.G13D mutation had a significantly lower ORR (9 studies; RR, 0.540; 95% CI, 0.381‐0.765) and nonsignificantly shorter PFS (1 study; HR, 0.99; 95% CI, 0.68‐1.45) and OS (1 study; HR, 1.01; 95% CI, 0.66‐1.54). CONCLUSIONS: Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations. However, because of the limited sample sizes in the current meta‐analysis, these results should be interpreted with caution. Cancer 2013. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · cited 2×
“Perkins 2010(20) France 42 60 [44-78] 24 (57) 3 (7) 1 (2) 4 (10) 15 (36) 23(55) DS RECIST Bando 2011(16) Japan 30 NA NA 0 (0) 0 (0) 7 (23) 23 (77) NA NA NA Tejpar 2011(17) Belgium 689 NA NA 0 (0) 689 (100) 42 (6) 249 (36) 398(58) NA NA”
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 3×
“Perkins 2010(20) France 42 60 [44-78] 24 (57) 3 (7) 1 (2) 4 (10) 15 (36) 23(55) DS RECIST Bando 2011(16) Japan 30 NA NA 0 (0) 0 (0) 7 (23) 23 (77) NA NA NA Tejpar 2011(17) Belgium 689 NA NA 0 (0) 689 (100) 42 (6) 249 (36) 398(58) NA NA”
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · cited 2×
“Moroni 2005(13) Italy 21 72 [41-85] 17 (81) 12 (57) 11 (52) 1 (5) 4 (19) 16(76) DS RECIST Lievre 2006(6) France 30 62 [41-78] 19 (63) 1 (3) 3 (10) 3 (10) 10 (33) 17(57) DS RECIST Benvenuti 2007(18) Italy 22 68 [39-84] 17 (77) 12 (55) 11 (50) 1 (5) 4 (18) 17(77) DS RECIST Frattini 2007(14) Switzerland 27 67 [29-84] 18…”
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540 · cited 1×
“Moroni 2005(13) Italy 21 72 [41-85] 17 (81) 12 (57) 11 (52) 1 (5) 4 (19) 16(76) DS RECIST Lievre 2006(6) France 30 62 [41-78] 19 (63) 1 (3) 3 (10) 3 (10) 10 (33) 17(57) DS RECIST Benvenuti 2007(18) Italy 22 68 [39-84] 17 (77) 12 (55) 11 (50) 1 (5) 4 (18) 17(77) DS RECIST Frattini 2007(14) Switzerland 27 67 [29-84] 18…”
Cited by
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9807 · Cited by 360
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82826 · Cited by 155
Receipt of Targeted Therapy and Survival Outcomes in Patients with Metastatic Colorectal Cancer
Koroukian, S. M., Booker, B. D., Vu, L., Schumacher, F. R., Rose, J., Cooper, G. S., Selfridge, J. E., & Markt, S. C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.50030 · Cited by 27
Metadata
- Authors
- Mao, C., Huang, Y., Yang, Z., Zheng, D., Chen, J., & Tang, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-09-12
- Volume
- 119
- Issue
- 4
- Pages
- 714-721
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1592610846
- Cited by
- 99
- References
- 9
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.